AbbVie Achieves Phase 3 Primary and All Secondary Endpoints for Atogepant in Menstrual Migraine

With no approved therapy currently on the market for menstrual migraine, AbbVie's Phase 3 LUNA readout for atogepant positions the company for a new indication filing that will carry distinct CMC and scale-up considerations for a CGRP receptor antagonist already in commercial production.

Topline data from the LUNA study, published 10 September 2026, showed atogepant met its primary endpoint and all eight ranked secondary endpoints versus placebo (p<0.0001 across all). Patients received atogepant for seven consecutive days beginning three days before menses onset, repeated across three menstrual cycles. The primary endpoint, reduction in migraine days during the perimenstrual period averaged over the double-blind period, showed a mean reduction of 1.20 days with atogepant versus 0.40 days with placebo, a difference of 0.80 days (p<0.0001). Secondary endpoints spanned headache burden, acute medication use, functional disability, cognitive function, and responder outcomes.

Safety results were consistent with atogepant's established profile; no new signals were observed. That continuity matters for regulatory strategy: a supplemental filing built on an unchanged safety database typically supports a more streamlined 21 CFR Part 314 sNDA pathway, though health authority alignment will depend on how AbbVie frames the episodic dosing regimen, seven-day cycles rather than continuous daily administration, relative to existing labeling.

For manufacturing and QA teams, the cyclic dosing model introduces a demand-pattern variable that differs from chronic preventive use. Batch scheduling, shelf-life management across a patient population with predictable monthly consumption windows, and packaging configurations aligned to a seven-day course will each require process validation review under ICH Q10 principles before commercial scale-up for the new indication. AbbVie has indicated plans to submit LUNA data to health authorities worldwide, with congress presentations to follow.

The European Migraine and Headache Alliance survey cited in the release noted that 68% of respondents with perimenstrual attacks reported never having been offered a tailored treatment approach, a figure that frames the unmet need regulators will weigh alongside the efficacy data.

The submission timeline and any required bridging studies for the cyclic regimen will serve as the measurable checkpoint for operations and regulatory teams tracking this program's path to approval.

Source: AbbVie News Center via PR Newswire, 10 September 2026.